Repligen | RGEN - Ordinary Share Capital


Repligen reported $56.32M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Agilent USD 282.7M 358K Dec/2025
Align Technology USD 71.75M 736K Dec/2025
Bio Techne USD 155.75M 154.18M Sep/2025
BioMarin Pharmaceutical USD 192.3M 201K Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Bruker USD 151.94M 225K Dec/2025
Charles River Laboratories USD 49.22M 2K Dec/2025
Danaher USD 706.9M 600K Dec/2025
Dentsply International USD 199.5M 196.5M Sep/2025
Exact Sciences USD 189.45M 232K Sep/2025
General Electric Aerospace USD 1.05B 6.05M Dec/2025
Henry Schein USD 115.77M 2.8M Dec/2025
Illumina USD 152.8M 900K Dec/2025
IQVIA Holdings USD 169.6M 700K Dec/2025
Mettler Toledo International USD 20.43M 170.6K Dec/2025
Myriad Genetics USD 93.1M 0 Sep/2025
OraSure Technologies USD 0 0 Jun/2024
Pacific Biosciences Of California USD 258K 8K Sep/2023
Pfizer USD 5.69B 1000K Sep/2025
Repligen USD 56.32M 42K Dec/2025
Revvity USD 113.38M 2.7M Dec/2025
Standard Biotools USD 383.61M 383.22M Sep/2025
Thermo Fisher Scientific USD 375.71M 1.9M Dec/2025
Waters USD 98.08M 38.55M Dec/2025
West Pharmaceutical Services USD 72M 100K Dec/2025